Innovation Failure Index: 10 AI Firms Missing Outcomes

The healthcare AI landscape, frequently lauded for its transformative potential, often generates significant buzz around technological breakthroughs, funding rounds, and media accolades. Yet, for investors and industry analysts, the true measure of innovation lies not in novelty or press coverage, but in validated clinical outcomes and real-world impact. While the industry celebrates Fast Company’s 2026 “Most Innovative Companies” recognition for Hello Heart’s ability to provide a 10-day early cardiac warning, a stark contrast to the standard 10-year clinical risk model, this success story highlights a critical divergence: many ventures innovate on everything except the patient-centric results that truly matter.

This editorial delves into an “Innovation Failure Index,” examining ten prominent healthcare AI companies that, despite significant investment and media attention, have struggled to demonstrate consistent, positive clinical outcomes. Our analysis frames these cases through the lens of our publication’s core mission: weighting clinical outcomes over technological novelty, focusing instead on real-population testing, published results, and measurable clinical impact.

The Chasm Between Hype and Health: Early AI Disappointments

The narrative of healthcare AI is replete with cautionary tales where ambition outstripped evidence. IBM Watson Health, which had its healthcare data and analytics assets acquired by Francisco Partners in 2022 and rebranded as Merative, stands as a primary example. Despite its immense resources and initial promise to revolutionize oncology, its clinical utility remained largely unsubstantiated. As figures like Eric Topol have frequently pointed out, the gap between Watson’s advertised capabilities and its actual performance in complex clinical settings became a significant concern. The investment poured into this venture, combined with a notable absence of robust, peer-reviewed clinical outcomes, serves as a potent reminder of how easily technological prowess can be conflated with genuine healthcare innovation.

Similarly, Theranos, though not strictly an AI company, embodies the perils of an innovation narrative detached from scientific rigor and clinical validation. Its spectacular rise and fall, meticulously documented by journalists like Casey Ross, demonstrated how a compelling story and significant funding could mask a fundamental lack of proven clinical efficacy. The lessons from Theranos resonate deeply in the AI space, emphasizing that for Investors and VCs, the due diligence must extend far beyond the pitch deck to scrutinize the underlying science and real-world data.

The Innovation Treadmill: Companies That Missed the Outcomes Mark

Several other companies, despite attracting substantial capital and media attention, have struggled to translate their technological innovations into verifiable clinical impact. Olive AI, which ultimately ceased independent operations in late 2023 after selling its business units to Waystar and Humata Health, for instance, championed AI-driven automation for administrative tasks in healthcare. While the promise of efficiency was compelling, the widespread, documented clinical benefits directly attributable to its solutions remained elusive. The focus often shifted to cost savings and operational improvements, which, while valuable, are distinct from direct patient outcome enhancements. Rock Health reports on healthcare AI investment trends

Babylon Health, which filed for Chapter 7 bankruptcy in the US in August 2023 and had its UK business acquired by eMed Healthcare, was an ambitious digital health provider that expanded rapidly with AI-powered symptom checkers and virtual consultations. However, its clinical claims and diagnostic accuracy came under scrutiny, with questions raised about the robustness of its evidence base. The scale of its operations and media presence often overshadowed the critical need for rigorous validation of its AI’s clinical effectiveness in diverse patient populations.

The digital therapeutics space, too, offers salient examples. Pear Therapeutics, which filed for Chapter 11 bankruptcy in April 2023 and sought to sell its assets, was a pioneer in prescription digital therapeutics (PDTs) with FDA De Novo clearances for conditions like substance use disorder and insomnia, but faced significant challenges in achieving widespread adoption and demonstrating sustained, scalable clinical impact in real-world settings. Despite regulatory milestones, the pathway from clearance to consistent patient outcomes and reimbursement proved arduous. Proteus Digital Health, which filed for Chapter 11 bankruptcy in June 2020 and had its assets acquired by Otsuka Pharmaceutical in August 2020, with its ingestible sensors for medication adherence, similarly innovated on technology but struggled with the complexities of integrating its solution into clinical workflows and proving long-term, cost-effective patient benefits. Their journey underscores the difficulty of translating even FDA-cleared innovation into tangible clinical value without a clear path to sustained outcomes.

Beyond the Clinic: Operational Innovation Without Clinical Return

Some companies focused their innovation on delivery models or operational efficiencies, yet still faced challenges in demonstrating direct, measurable clinical improvements. Forward Health aimed to reinvent primary care with technology and a membership model. While offering a high-tech patient experience, the concrete evidence of superior clinical outcomes compared to traditional primary care models remained a point of debate. Similarly, Cerebral and Hims & Hers leveraged telehealth platforms to scale access to mental health and other medical services. While addressing access gaps is a form of innovation, controversies surrounding their clinical practices, prescribing patterns, and the quality of care delivered highlighted that expanding access without robust clinical governance and outcome measurement can lead to significant pitfalls. These cases illustrate that innovation in healthcare delivery must be inextricably linked to improving clinical outcomes, not just access or convenience.

Even tech giants have stumbled. Google Health, despite its vast resources and AI expertise, faced challenges in establishing a coherent strategy and demonstrating consistent clinical impact across its various initiatives. The fragmentation of efforts and the difficulty in navigating the complex healthcare ecosystem often overshadowed the potential of its underlying AI technologies. As Ziad Obermeyer’s work often emphasizes, the application of AI in healthcare demands a deep understanding of clinical context and a rigorous approach to evidence generation, areas where even well-resourced entities can falter.

Regulatory Context and the Investment Imperative

The regulatory landscape, particularly the FDA’s Software as a Medical Device (SaMD) Framework and the De Novo classification pathway, has provided mechanisms for novel AI-driven healthcare solutions to enter the market. However, regulatory clearance is not synonymous with clinical impact or commercial success. As Rock Health and CB Insights reports consistently show, significant investment has flowed into companies achieving these clearances, but the subsequent challenge of demonstrating real-world clinical utility and securing sustainable reimbursement remains. Many of the companies discussed here, despite raising substantial capital (CW3-DP-01; CW3-DP-03) and sometimes achieving regulatory milestones, ultimately failed to produce the published clinical outcomes that would justify their valuations or ensure their longevity. CB Insights reports on failed healthcare AI ventures

This disconnect highlights a critical lesson for Investors and VCs: while technological innovation and regulatory approval are necessary, they are insufficient. The “innovation investment with zero published clinical outcomes” relationship observed across many of these cases underscores a systemic issue. Companies that prioritize patent counts, funding raised, and press coverage over rigorous real-population testing and published results often find themselves in an unsustainable position.

The Path Forward: Prioritizing Outcomes in Healthcare AI Investment

The stories of IBM Watson Health, Theranos, Olive AI, Babylon Health, Pear Therapeutics, Proteus Digital Health, Forward Health, Cerebral, Hims & Hers, and Google Health offer invaluable lessons. For Investors and Industry Analysts, the key takeaway is clear: true innovation in healthcare AI is measured by clinical impact, not just technological novelty or market hype. The ability of a solution to demonstrate meaningful improvements in patient outcomes, supported by robust real-population testing and published results, must be the paramount criterion. Moving forward, the industry must demand greater transparency and accountability, shifting the focus from the promise of AI to its proven performance in improving health.